Compare GLDD & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLDD | KOD |
|---|---|---|
| Founded | 1890 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2007 | 2018 |
| Metric | GLDD | KOD |
|---|---|---|
| Price | $16.89 | $25.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $20.00 | ★ $28.29 |
| AVG Volume (30 Days) | ★ 1.8M | 645.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 300.00 | 32.60 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $702,503,000.00 | N/A |
| Revenue This Year | $13.16 | N/A |
| Revenue Next Year | $5.49 | N/A |
| P/E Ratio | $18.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.51 | $1.92 |
| 52 Week High | $16.99 | $31.18 |
| Indicator | GLDD | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 70.36 | 53.93 |
| Support Level | $16.85 | $21.51 |
| Resistance Level | $16.92 | $27.99 |
| Average True Range (ATR) | 0.37 | 2.02 |
| MACD | 0.05 | 0.33 |
| Stochastic Oscillator | 95.82 | 66.67 |
Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.